Ohio State University Medical Center has received a $9.1 million federal grant for research aimed at reducing the number of adverse drug reactions among patients on medication.
The five-year grant comes from the National Institute of General Medical Sciences. The study will be led by Wolfgang Sadee, who chairs Ohio State’s pharmacogenomics program, according to a statement from the OSU Medical Center.
On Tuesday, the National Institutes of Health said it had committed to invest $161.3 million over five years to expand the Pharmacogenomics Research Network, a nationwide collaboration of scientists focused on understanding how genes affect a person’s response to medicines.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
“We want to improve our ability to give the right drug to the right patient at the right time at the right dosage,” Sadee said.
Sadee estimated that 30-to-70 percent of people who take medications don’t respond favorably or experience adverse reactions. Much of that may be due to genetic differences in people that cause their bodies to respond to medication in different ways. Sadee’s research will focus on identifying the genetic differences so researchers can predict which drugs will be most suitable for certain patients.
“Our project uses a novel approach to finding these critical genetic differences and testing them immediately in clinical trials that are under way here at Ohio State and across the world,” he said.
In addition to Sadee’s research, the grant funds Ohio State as a member of the nationwide Pharmacogenomics Research Network, which connects 14 research centers across the U.S. that are working towards improving drug response rates and decreasing adverse medication events, according to the statement.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.